Everest Medicines Licensing Partner Reports Positive Phase 2a Data for Wet AMD Treatment
Event summary
- Everest Medicines’ licensing partner, NovaBridge, and its subsidiary Visara, announced positive topline results from a Phase 2a study of VIS-101 for wet AMD.
- The study, conducted in China, enrolled 38 patients and demonstrated mean BCVA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm.
- VIS-101 showed potential best-in-class durability, with approximately two-thirds of patients remaining retreatment-free at 4 months.
- A dose-determining Phase 2b study is planned for H2 2026, followed by a global Phase 3 program in 2027.
- Everest Medicines holds an exclusive license to develop and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries, acquired on October 30, 2025.
The big picture
The positive Phase 2a data for VIS-101 validates the dual VEGF-A/ANG-2 inhibition approach for treating wet AMD, a market with over 20 million patients globally. Everest Medicines’ licensing agreement represents a strategic expansion into the ophthalmology space, leveraging its commercialization platform in Asia. The durability data, if confirmed in later trials, could represent a significant advantage over existing treatments, which often require frequent injections.
What we're watching
- Clinical Progression
- The success of the Phase 2b dose-determining study will be critical to validating the observed efficacy and safety profile, and will dictate the timeline for a global Phase 3 trial.
- Commercial Execution
- Everest Medicines’ ability to navigate regulatory approvals and establish market access in its licensed territories will determine the commercial viability of VIS-101.
- Competitive Landscape
- The emergence of VIS-101 will likely intensify competition within the wet AMD treatment market, potentially impacting pricing and market share for existing therapies.
Related topics